Oncology

Latest News

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com
COA 2025: Insight, Innovation, and Independent Strength

May 5th 2025

The 2025 Community Oncology Conference empowered attendees with insights on advocacy, innovation, and practical strategies for enhancing community cancer care.

COA logo | Image Credit: © Amy Kinnamon
Community Oncology Reacts to Trump's Drug Pricing Executive Order

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com
5 Things You Should Know About Skin Cancer

May 2nd 2025

stethoscopewithcompass | Image Credit: © Talaj-stock.adobe.com
Patient Navigation Is Nonnegotiable in Cancer Care

May 1st 2025

Liver cancer - Sebastian Kaulitzki - stock.adobe.com.jpg
Elevated HLA-G Seen in HCC Driven by Viral Infections, Fatty Liver

May 1st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

NGS Identifies Survival, Treatment Outcomes for Patients With CRC Genetic Mutations
April 7th 2019

NGS Identifies Survival, Treatment Outcomes for Patients With CRC Genetic Mutations

Laura Joszt, MA
Genetic alternations in colorectal cancer (CRC) are linked to different survival and treatment outcomes, according to a study that used next-generation sequencing (NGS) of tumor DNA. The study was published in Journal of Clinical Oncology.
Abra Kelson Outlines How Early Intervention Strategies Can Benefit Patient Treatment
April 5th 2019

Abra Kelson Outlines How Early Intervention Strategies Can Benefit Patient Treatment

Early intervention to identify social needs means issues get caught sooner and patients can avoid or minimize financial toxicity, said Abra Kelson, MSW, LSWA-IC, medical social work supervisor, Northwest Medical Specialties.
Site Logo
April 5th 2019

COA Close to Filing OCM 2.0 for Federal Review

Mary Caffrey
The first day of the 2019 Community Oncology Conference, the major annual meeting of the Community Oncology Alliance (COA), featured an update on its effort to find alternatives to CMS' Oncology Care Model.
Ben Jones Explains Reimbursement Challenges Facing Community Oncologists
April 4th 2019

Ben Jones Explains Reimbursement Challenges Facing Community Oncologists

There's still a big disparity in reimbursement between hospitals and community-based practices, but is looking into ways to address this, explained Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health.
Site Logo
April 2nd 2019

The PAN Foundation Opens New Waldenstrom Macroglobulinemia Patient Assistance Fund

The Patient Access Network (PAN) Foundation today opened a new patient assistance program for people living with Waldenstrom macroglobulinemia, a rare type of blood cancer that originates in the lymphatic system and is characterized by an excess of abnormal white blood cells and proteins called immunoglobulins.
MyPath, an App That Uses AI to Guide Patients' Cancer Journeys
April 2nd 2019

MyPath, an App That Uses AI to Guide Patients' Cancer Journeys

Today we’re speaking with Dr Elizabeth Mynatt, the executive director of the Institute for People and Technology and a professor in the College of Computing at the Georgia Institute of Technology. Dr Mynatt and her team developed an app called MyPath that uses artificial intelligence to help guide a patient’s cancer journey.
Value-Based Care Is Changing Cancer Treatment Decisions as Drug Costs Continue to Rise
March 31st 2019

Value-Based Care Is Changing Cancer Treatment Decisions as Drug Costs Continue to Rise

Laura Joszt, MA
As novel therapies drive up the cost of drugs, it is becoming increasingly difficult for community oncologists to keep costs below value-based care program targets, according to a new survey from Integra Connect.
Not Just the "Soft Stuff": How Data Deployment, Artificial Intelligence Can Restore Relationships in Oncology Care
March 30th 2019

Not Just the "Soft Stuff": How Data Deployment, Artificial Intelligence Can Restore Relationships in Oncology Care

Mary Caffrey
The revolution in cancer care isn’t just about the wave of life-saving therapies, or the role of genetics in pinpointing exactly who should get which drug and when. As Ray D. Page, DO, PhD, FACOI, tells it, change also means getting back to the basics, so that the relationship between doctor and patient drives care—not insurance companies or Medicare or rules from the FDA.
Heard at ACCC: Addressing Challenges With Cancer Care Delivery With Tom Gallo and Dr Ali McBride
March 28th 2019

Heard at ACCC: Addressing Challenges With Cancer Care Delivery With Tom Gallo and Dr Ali McBride

Tom Gallo, the former president of the Association of Community Cancer Centers (ACCC), and Ali McBride, PharmD, the current president of ACCC, discuss how their members feel about the state of cancer delivery, recent trends, addressing burnout, and sustainability of cancer care delivery.
Racially Diverse Cell Lines Needed for Precision Medicine to Reach Underrepresented Populations
March 27th 2019

Racially Diverse Cell Lines Needed for Precision Medicine to Reach Underrepresented Populations

Laura Joszt, MA
A lack of diversity in cell lines used for laboratory studies means underrepresented populations and minorities might not benefit from precision medicines as quickly as people from European ancestry.
Site Logo
March 27th 2019

Ali McBride, PharmD, MS, BCOP, Becomes ACCC President 2019-2020

Ali McBride, PharmD, MS, BCOP, was named 2019-2020 president of the Association of Community Cancer Centers (ACCC) during its 45th Annual Meeting & Cancer Center Business Summit on March 22, 2019, in Washington, DC. McBride is the clinical coordinator of hematology/oncology at The University of Arizona Cancer Center.
Jessa Dunivan: Cohesiveness Is Vital to Maintaining a Successful Care Management Team
March 27th 2019

Jessa Dunivan: Cohesiveness Is Vital to Maintaining a Successful Care Management Team

Everyone at the practice is vital to the success of value-based care, which is really patient-centered care, said Jessa Dunivan, patient services manager, Northwest Medical Specialties.
Dr Ali McBride Discusses the Role of Biosimilars in Oncology
March 25th 2019

Dr Ali McBride Discusses the Role of Biosimilars in Oncology

At the Association of Community Cancer Centers (ACCC)'s 45th Annual Meeting & Cancer Center Business Summit, Ali McBride, PharmD, MS, BCPS, BCOP, clinical coordinator of hematology/oncology in the Department of Pharmacy at The University of Arizona Cancer Center and president of ACCC, discussed the role of biosimilars in oncology and how familiar oncologists and their teams are with them.
Dr Jarushka Naidoo Discusses Evolution of Biomarker Testing
March 25th 2019

Dr Jarushka Naidoo Discusses Evolution of Biomarker Testing

Biomarker testing will start to evolve to look more at combination therapies, said Jarushka Naidoo, MB BCh, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Dr Toby Campbell Outlines the Importance of Early End-of-Life Care Discussions
March 25th 2019

Dr Toby Campbell Outlines the Importance of Early End-of-Life Care Discussions

The move to value-based care has increased the use of palliative care, and new research has found that conversations about end-of-life care should be happening earlier, said Toby C. Campbell, MD, MSCI, of the University of Wisconsin Carbone Cancer Center.
Abra Kelson Discusses Screening Measures to Highlight High-Risk Patients Who Need Assistance
March 24th 2019

Abra Kelson Discusses Screening Measures to Highlight High-Risk Patients Who Need Assistance

There are a lot of different ways for identifying patients that might have barriers to care or might be considered as high-risk, says Abra Kelson, MSW, LSWA-IC, medical social work supervisor, Northwest Medical Specialties.
Dr Gary Lyman Sees Knowledge of Biosimilars in Cancer Has Improved
March 24th 2019

Dr Gary Lyman Sees Knowledge of Biosimilars in Cancer Has Improved

Although there is still a need for more education around the use of biosimilars in cancer, it seems oncologists have become more knowledgeable in the past few years, said Gary H. Lyman, MD, MPH, of Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance.
Podcast: This Week in Managed Care—Cardiovascular Prevention Guidelines and Other Health News
March 24th 2019

Podcast: This Week in Managed Care—Cardiovascular Prevention Guidelines and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Erich Mounce Discusses How Community Oncology Can Address Inequalities in Cancer Care
March 23rd 2019

Erich Mounce Discusses How Community Oncology Can Address Inequalities in Cancer Care

Erich Mounce, chief operating officer, OneOncology, drew on his experience from West Cancer Center to discuss how community oncology can improve access to care and other inequalities in cancer care.
FDA Stops Enrollment in Phase 3 MM Trial Due to 2-Fold Increase in Mortality
March 22nd 2019

FDA Stops Enrollment in Phase 3 MM Trial Due to 2-Fold Increase in Mortality

Samantha DiGrande
This week, the FDA sent out an alert to various healthcare professionals and the public to warn about the risks associated with the investigational use of venetoclax (Venclexta) for the treatment of patients with multiple myeloma (MM). The alert is based on data from the ongoing phase 3 BELLINI trial evaluating the drug for this treatment.
Feyi Olopade Ayodele Highlights How CancerIQ Helps With Genetic Testing
March 22nd 2019

Feyi Olopade Ayodele Highlights How CancerIQ Helps With Genetic Testing

CancerIQ is reducing barriers that make it difficult to utilize genetic testing to predict or pre-empt a patient’s cancer diagnosis, explained Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
This Week in Managed Care: March 22, 2019
March 22nd 2019

This Week in Managed Care: March 22, 2019

This week, the top managed care news included new primary prevention guidelines that could increase the use of some diabetes drugs; the FDA expanded criteria for which patients can take part in clinical trials; a summit on value-based insurance design showed the need for tough conversations with stakeholders.
Dr John Ward on Conversations With Patients After Multigene Testing
March 22nd 2019

Dr John Ward on Conversations With Patients After Multigene Testing

Multigene testing provides a lot of information that providers have to be familiar with in order to adequately explain it to their patients, said John H. Ward, MD, Huntsman Cancer Institute at the University of Utah.
Dr John Sweetenham Discusses the Impact of CMS' Proposal on Access to CAR T-Cell Therapies
March 22nd 2019

Dr John Sweetenham Discusses the Impact of CMS' Proposal on Access to CAR T-Cell Therapies

CMS’ proposal that patients be enrolled in a clinical trial or registry to get Medicare coverage for chimeric antigen receptor (CAR) T-cell therapies will help improve access, for the most part, but there is the risk that some organizations will choose not to offer this treatment, said John W. Sweetenham, MD, of Huntsman Cancer Institute at the University of Utah.
Site Logo
March 22nd 2019

Different Vantage Points, but Similar Goals of High-Value Care, Patient Satisfaction

Laura Joszt, MA
A diverse panel of representatives from different practice models provided insights into what has worked for them and what has not in trying to improve cancer care. The discussion took place in Washington, DC, at the Association of Community Cancer Centers
Dr Allen Lichter: Technology Is Present in Oncology, but the Future Is Brighter
March 21st 2019

Dr Allen Lichter: Technology Is Present in Oncology, but the Future Is Brighter

While there is currently a presence of technology in healthcare, the future holds much more promise, said Allen Lichter, MD, FASCO, senior partner of TRG Healthcare.
Genomic Testing Can Reduce Costs by $6600 for Certain Patients With Breast Cancer
March 20th 2019

Genomic Testing Can Reduce Costs by $6600 for Certain Patients With Breast Cancer

Laura Joszt, MA
Patients with high-risk breast cancer who receive a 21-gene assay genomic test may be able to avoid chemotherapy and ultimately save a significant amount of money.
Beth Wittmer Discusses Potential Reasons Patients Delay Seeking Treatment
March 20th 2019

Beth Wittmer Discusses Potential Reasons Patients Delay Seeking Treatment

Fear and denial can contribute to a patient’s hesitancy to seek prompt treatment, says Beth Wittmer, RN, OCN, manager of care management at Florida Cancer Specialists and Research Institute.
COA 2019: On Location Interviews, Day 2
March 19th 2019

COA 2019: On Location Interviews, Day 2

On day 2 of the Community Oncology Alliance's annual Community Oncology Conference, held April 4-5 in Orlando, Florida, we spoke with Debra Patt, MD, MPH, MBA, executive vice president of Texas Oncology, and Jeffrey Vacirca, MD, chief executive officer of New York Cancer & Blood Specialists.
COA 2019: On Location Interviews, Day 1
March 19th 2019

COA 2019: On Location Interviews, Day 1

On day 1 of the Community Oncology Alliance (COA)'s annual Community Oncology Conference, held April 4-5 in Orlando, Florida, we spoke with Ted Okon, executive director of COA, and Sibel Blau, MD, medical director of Northwest Medical Specialties, PLLC.
<1
...
272829303132333435
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo